Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04903288 · ClinicalTrials.gov registry record · Phase 2
A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Participants
A Phase 2 study of AADC Deficiency, sponsored by PTC Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
- 6
- Study locations
NCT04903288 is a Phase 2 study of AADC Deficiency that is active but no longer recruiting, run by PTC Therapeutics. The registered enrollment target is 13 participants. The trial reports 6 study locations across 5 states.
The verdict
NCT04903288, a Phase 2 study of AADC Deficiency, is active but no longer recruiting, sponsored by PTC Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study will have a trial phase, extension phase, and a long-term extension phase. The primary objectives of the trial phase are to assess the pharmacodynamics (PD) of eladocagene exuparvovec treatment by evaluation of homovanillic acid (HVA) levels and to assess the safety of the SmartFlow® magnetic resonance (MR) Compatible Ventricular Cannula for administering eladocagene exuparvovec to pediatric participants with aromatic L-amino acid decarboxylase (AADC) deficiency. The extension phase is designed to capture additional clinical information for eladocagene exuparvovec through study evaluations, changes in motor development, AADC-specific symptoms, and other PD measures. The long-term extension phase is designed to capture long-term safety and efficacy data from participants treated with eladocagene exuparvovec.
Conditions Studied
Interventions
- GENETIC Eladocagene Exuparvovec
Study Locations (6)
Other
- Chaim Sheba Medical Center - Ramat Gan
- National Taiwan University Hospital, Department of Pediatrics and Medical Genetics - Taipei
Massachusetts
- Boston Children's Hospital - Boston
North Carolina
- Duke University Hospital - Durham
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Texas
- Texas Children's Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-05-12 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04903288
The ClinicalTrials.gov registry entry for NCT04903288 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PTC Therapeutics, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with AADC Deficiency appearing as the primary indexed condition, and to 1 intervention - of which Eladocagene Exuparvovec is the first listed.
NCT04903288 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Other, Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT04903288 about?
NCT04903288 is a clinical study titled "A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Participants". This study will have a trial phase, extension phase, and a long-term extension phase. The primary objectives of the trial phase are to assess the pharmacodynamics (PD) of eladocagene exuparvovec treatment by evaluation of homovanillic acid (HVA) levels and to assess the safety of the SmartFlow® magn...
What is the current status of trial NCT04903288?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2021-05-12. Estimated completion is 2028-04-30.
What conditions does trial NCT04903288 study?
This clinical trial studies the following conditions: AADC Deficiency.
What interventions are being tested in trial NCT04903288?
The interventions under investigation include: Eladocagene Exuparvovec (GENETIC).
Who is sponsoring clinical trial NCT04903288?
This trial is sponsored by PTC Therapeutics, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04903288 being conducted?
This trial has 6 study locations across Massachusetts, North Carolina, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for AADC Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.